Effect of Low Doses of Atorvastatin on the Urinary Peptide Profile of Kidney Transplant Patients

Transplantation Proceedings

Volumn 41, Issue 6, 2009, Pages 2111-2114

  Perez V ^a   Navarro Munoz M ^a   Bayes B ^a   Lauzurica, R ^a   Pastor, M C ^a   Troya, M ^a   Bonet, J ^a   Ibernon M ^a   Navarro, M ^a   Serra, A ^a   Nunez A ^b   Romero, R ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; AZATHIOPRINE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEPTIDE; PREDNISONE; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEINURIA; PROTEOMICS; RECIPIENT; TREATMENT OUTCOME; URINALYSIS;

ADULT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIPIDS; MALE; MIDDLE AGED; PEPTIDES; PYRROLES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRIGLYCERIDES;

EID: 68949220137     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.170     Document Type: Article

References (8)

1. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol 21 (2001) 3
2. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712
3. Bayes B., Granada M.L., Lauzurica R., et al. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients. Transplant Proc 37 (2005) 3808
4. Decramer S., Gonzalez de Peredo A., Breuil B., et al. Urine in clinical proteomics. Mol Cell Proteomics 7 (2008) 1850
5. Fiedler G.M., Baumann S., Leichtle A., et al. Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 53 (2007) 421
6. Kasiske B., Cosio F.G., Beto J., et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 4 suppl 7 (2004) 13
7. Shepherd J., Kastelein J.J., Bittner V., et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) Study. Clin J Am Soc Nephrol 2 (2007) 1131
8. Navarro-Munoz M., Bonet J., Bayes B., et al. Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation?. Transplant Proc 39 (2007) 2259